• Like
The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back

  • 211 views
Published

Slides presented at the University of Edinburgh in Jan 2014, based on our paper "A tale of two drug targets: the evolutionary history of BACE1 and BACE2" …

Slides presented at the University of Edinburgh in Jan 2014, based on our paper "A tale of two drug targets: the evolutionary history of BACE1 and BACE2" http://www.ncbi.nlm.nih.gov/pubmed/24381583

The beta amyloid (APP) cleaving enzyme (BACE1) has been a drug target for Alzheimer's Disease (AD) since 1999 with lead inhibitors now entering clinical trials. In 2011, the paralog, BACE2, became a new target for type II diabetes (T2DM) having been identified as a TMEM27 secretase regulating pancreatic β cell function. However, the normal roles of both enzymes are unclear. This study outlines their evolutionary history and new opportunities for functional genomics. We identified 30 homologs (UrBACEs) in basal phyla including Placozoans, Cnidarians, Choanoflagellates, Porifera, Echinoderms, Annelids, Mollusks and Ascidians (but not Ecdysozoans). UrBACEs are predominantly single copy, show 35–45% protein sequence identity with mammalian BACE1, are ~100 residues longer than cathepsin paralogs with an aspartyl protease domain flanked by a signal peptide and a C-terminal transmembrane domain. While multiple paralogs in Trichoplax and Monosiga pre-date the nervous system, duplication of the UrBACE in fish gave rise to BACE1 and BACE2 in the vertebrate lineage. The latter evolved more rapidly as the former maintained the emergent neuronal role. In mammals, Ka/Ks for BACE2 is higher than BACE1 but low ratios for both suggest purifying selection. The 5' exons show higher Ka/Ks than the catalytic section. Model organism genomes show the absence of certain BACE human substrates when the UrBACE is present. Experiments could thus reveal undiscovered substrates and roles. The human protease double-target status means that evolutionary trajectories and functional shifts associated with different substrates will have implications for the development of clinical candidates for both AD and T2DM. A rational basis for inhibition specificity ratios and assessing target-related side effects will be facilitated by a more complete picture of BACE1 and BACE2 functions informed by their evolutionary context.

Published in Technology , Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
211
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
6
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The Beta Amyloid Cleaving Enzymes: From Drug Discovery to Evolution and Back 17th January 2014, QMRI, University of Edinburgh Christopher Southan, IUPHAR Database and Guide to PHARMACOLOGY Web Portal Group, Queen's Medical Research Institute, University of Edinburgh, UK http://cdsouthan.blogspot.se/2014/01/a-tale-of-two-targets-bace1-and-bace2.html http://www.guidetopharmacology.org/ cdsouthan@hotmail.com Orchid ID 0000-0001-9580-0446 Twitter: http://twitter.com/#!/cdsouthan Blog: http://cdsouthan.blogspot.com/ LinkedIN: http://www.linkedin.com/in/cdsouthan Presentations: http://www.slideshare.net/cdsouthan [1]
  • 2. Reference and Acknowledgment PMID:24381583 (2013) [2]
  • 3. Presentation Outline • • • • • • • • • • Introducing the BACE1 and BACE2 Aspartyl proteases BACE1 as an Alzheimer’s disease (AD) target BACE2 as a Type II Diabetes (T2D) target Drug discovery > evolution - the three paralogs The chordate/vetebrate BACE1/2 evolutionary trajectory The ancestral UrBACE in basal animal phyla and oily tails Where the either the UrBACE or certain substrates are missing Corroboration by another paper Evolution back to drug discovery – functional genomics Evolution informs drug development [3]
  • 4. Starting Points [4]
  • 5. BACE1 Normal Function: Neuronal Pleiotropic • • • • • • • • • Review articles collate ~13 non-amyloidogenic in vivo substrates Suggested normal cleaved APP (P05067) ectodomain involvement nerve cells and Aβ peptide dampening of neuronal hyperactivity Voltage-gated sodium channel subunits (SCN4B, O60939) substrates for regulation of Nav1 channel metabolism Neuregulin(NRG1, Q022979) substrate for control of nerve cell myelination Amyloid-like protein 2 (APP2, Q06481) substrate for ectodomain fragments Pancreatic ectodomain shedding of broad set of β-cell-enriched substrates KO-mice subtle neurochemical deficits and behavioural changes Zebrafish KO substrates related to neurite outgrowth and axon guidance Zebrafish KO shows peripheral hypomyelination [5]
  • 6. BACE2 Normal Function : Peripheral Pleiotropic • • • • • • • • • • Similar to BACE1 in catalytic activity with a large open cleft Balance of evidence against being an APP beta secretase in vivo Broad tissue distribution attributable to different promoter usage to BACE1 KO mice “normal” Neonatal mortality increase in mouse double-KO (Bace1-/-; Bace2-/-) TMM27 (Q9HBJ8) secretase in mice and in human pancreatic β-cell membranes Pancreatic ectodomain shedding of narrow set of β-cell substrates Processes mouse pigment cell-specific Melanocyte Protein (Q60696) Zebrafish KO melanocyte migration phenotype. Zebrafish Double KO (Bace1-/-; Bace2-/-) viable does not enhance the single mutant phenotypes, indicating non-redundant functions [6]
  • 7. Incidence of Alzheimer's Disease (AD) (by millions vs age in USA) [7]
  • 8. Regulated Intramembrane Proteolysis (RIP): APP Secretases as AD Targets A-beta 1-42 (sp|P05067|672-713) http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4865 [8]
  • 9. BACE1 Inhibitor Phase I (discontinued) AZD3839, Ki 26.1 nM http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6931 [9]
  • 10. Incidence of Type 2 Diabetes (by millions world-wide) [10]
  • 11. BACE2 Target Validation: 10 years after BACE1 PMID:21907142 (2011) PMID:23506624 (2012) http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6540 [11]
  • 12. Global Drug Discovery Output for BACE1 (left) and BACE1 (right) Southan C, Varkonyi P, Boppana K, Jagarlapudi SA, et al. (2013) Tracking 20 Years of Compound-to-Target Output from Literature and Patents. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0077142 [12]
  • 13. Drug Discovery Output for BACE1 from UKPMC http://cdsouthan.blogspot.se/2013/11/drug-target-time-tracking.html [13]
  • 14. From Drug Discovery to Evolution PMID:12904811 (2003) [14]
  • 15. A Tale of three Paralogs (I) BACE1, Chromosome 11 BACE2, Chromosome 21 CATE, Chromosome 1 50% identity 27% identity Protein sequence comparison mRNA tissue distribution [15]
  • 16. A Tale of three Paralogs (II) InterProScan outputs CATE BACE1 BACE2 [16]
  • 17. Challenges in Finding Orthologs: Truncated ORFs from Genome Pipelines [17]
  • 18. Many Ensembl Orthologs have Errors 80 orthologs of BACE1 in Ensembl % target ID (blue) vs. % query ID [18]
  • 19. BACE in Chordates [19]
  • 20. BACE in Chordates • Ensembl has dense vertebrate coverage so we chose spaced sampling • Amphioxus outgroup consistent with protochordate 2R whole-genome duplication followed by paralog persistence • Distinctly accelerated evolution of BACE2 (neofunctionalisation ?) • Inferred neuronal role for BAC1 but no data outside human, mouse, fish • Long branches are partial sequences • Birds group with turtles • Coelacanth groups with reptiles and tetrapods (not ray-finned fish) • Xenopus laevis tetraploidisation has maintained “double” paralogs • No evidence for pseudogenes or “dead” variants • Implication of common origin between nerve and pancreatic cells [20]
  • 21. Rates of Recent Evolution Ka/Ks vs exon position for human/mouse/rat BACE1&2 0.25 Ka/Ks 0.2 0.15 BACE1 0.1 BACE2 0.05 0 Exon Exon Exon Exon Exon Exon Exon Exon Exon 1 2 3 4 5 6 7 8 9 • • Ka/Ks reflects the level of purifying selection Exon 1 is subject to weak selection while exons 4-6 are under strong selection (catalytic site) • Ka/Ks for BACE2 is on average twice that for BACE1 [21]
  • 22. Discovering the UrBACE: Human BACE1 vs Monosiga (Choanoflagellate) 33% identity over 432 residues, 9% gaps, divergence time ~0.8 billion years [22]
  • 23. Digging Deep: “BACE-like” Criteria • • • • • • • • • • Reciprocal BLAST highest score usually against a BACE1 Mostly single copies (i.e. just one UrBACE) Identity across the major part of the ORF < 35% without over-gapping Cathepsin paralogs drop to ~ 25% identity over ~350 residues with ~20% gapping Typically ~100 residues longer than cathepsins N-terminal signal peptide and a C-terminal transmembrane (CTM) either side of the protease domain CTM is absent from cathepsin paralogs although they also have Nterminal signal peptides Presence of diagnostic PRINTS matches, including at least one of the profiles for BACE, typically BACE1 Cathepsins and BACE2 sequences consistently showed two matches to the Prosite PS00141. UrBACEs showed only the single proximal Nterminal match. Iterating trees with different parameterizations, including cathepsins as out-groups, support the UrBACE grouping [23]
  • 24. The UrBACE Evolutionary Trajectory • After duplication from a cathepsin ancestor the emergence of the UrBACE protein sequence is distinct • Cathepsin paralogs form a clear outgroup • “Shuffling-in” of the CTM is the defining post-duplication shift in cellular location and function • Multiple divergent paralogs in basal phyla (2 in Monosiga, 3 in Trichoplax) predate the nervous system • Found in cnidaria with only nerve nets • Long branch lengths mainly due to partial sequences • Major orders now represented by draft genome assemblies • Basal relationships of Eumetazoans still unresolved • Beyond limited EST coverage no tissue distribution or functional data [24]
  • 25. UrBACEs and Cathepsin Paralogs [25]
  • 26. Oily Tails: the Key to Secretase Function BACE1 Spalmitoylati on at 4 Cys residues BACE2 UrBACE [26]
  • 27. Animal Lineages with no UrBACE Demosponge Non-orthologous replacement of UrBACE for pre- or post- neuronal RIP-related secretase functions ? [27]
  • 28. Detecting BACE1 and BACE2 substrate homologs: (note UrBACE + and APP -) BACE1 (P56817), APP (P05067), NRG1 (Q02297), SCN2B (O60939), TMEM27 (Q9HBJ8), and PSEN1 (P49768) for comparison X represents probable absence by low BLASTP score (score matrix in supplementary data) [28]
  • 29. The BACE that probably isn’t (because it’s a cathepsin sequence) Neurotoxic effects induced by the Drosophila amyloid-beta peptide suggest a conserved toxic function (PMID:19049874, 2009) • “We therefore propose that this fly enzyme represents an endogenous fly β-secretase and now named it dBACE” [29]
  • 30. Independent Corroboration Asynchronous Evolutionary Origins of Aβ and BACE1 (PMID:24361992, Dec 2013) “sequences homologous to Aβ are not found outside gnathostomes and the β cut site is only conserved within sarcopterygians. BACE1 enzymes, however, extend through basal chordates and as far as cnidaria. We then sought to determine whether BACE1 from a species that never evolved Aβ could proteolyze APP substrates which include Aβ. We demonstrate that BACE1 from a basal chordate is a functional ortholog that can liberate Aβ from full length human APP, indicating BACE1 activity evolved at least 360 million years before Aβ” Chinese Hamster Ovary cells transfected with human APP [30]
  • 31. From Evolution back to Drug Discovery PMID:23128209 PMID:23128209 http://en.wikipedia.org/wiki/Model_organism [31]
  • 32. Opportunities for Functional Genomics • • • • • • • • • • • UrBACE experiments to illuminate contemporary BACE roles and networks Comparative expression data to give clues KO or RNAi for protease or substrate ablation Mutants for more subtle perturbations Chemical perturbations with BACE1 and/or BACE2 inhibitors as probes Substitution options (e.g. swap UrBACE for human BACE1) Omics profiling for phenotypic read-out Smaller gene repertoires > simpler result interpretation UrBACE –ve and APP (like) +ve organisms as important controls Could detect UrBACE function shifts (e.g. pre and post-nervous system) Vertebrates will also show functional shifts for BACE1 and BACE1 (e.g. melanocyte role) [32]
  • 33. Evolution-informed Drug Development • Clinical candidate inhibitors face first-in-class challenges • Reciprocal specificity screening of both paralogs (in ChEMBL_17 the tested compound ratio for BACE1:BACE2 is 3999:563) • Specificity ratios (e.g. IC50s for BACE1:BACE2) will be chosen more carefully and factor-in brain penetration • New substrates verified in model organisms can be assessed for human side-effect liabilities and biomarkers • Substrate-specific inhibitor selectivity could be an option (e.g. neuregulinsparing) • Screen BACE1 leads in T2D models and BACE2 leads in AD models • Possible new lower organism phenotypic assays for BACE inhibitors, even with UrBACE • Important to develop pathway perspectives on both paralogs [33]
  • 34. Questions ? (and you can try your own phylogenies at home) http://figshare.com/articles/Supplementary_Data_for_Southan_Hancock_BACE_evolution_paper/855620 [34]